Unfortunately, the low labelling efficiency of 5'Cr limits the amount of radioactivity that can be administered in man,2 there is evidence that 5'Cr is toxic to platelets,3 and there may be mechanical damage to platelets during their harvesting from relatively large volumes of blood.' Results of platelet dynamic studies using the 51Cr label must, therefore, be interpreted with some caution, as 5'Cr tagged platelets may not be metabolically or structurally normal.
It is now agreed that "'1Indium-8-hydroxyquinolone ("'In-oxine) is an efficient and 'physiological' platelet label4 which, having a half life of 2.7 days, makes it ideally suited for measurements of platelet lifespan. Furthermore, the simple, rapid and easily reproducible technique of platelet labelling using less than 30 ml venous blood, introduced by Hawker, 6 allows studies on ill, anaemic, and thrombocytopenic patients.
We report here our further studies of platelet dynamics in chronic liver disease now using the lllIn-oxine label.
Received for publication 7 April 1982 Methods PATIENTS Twenty patients with biopsy-proven chronic liver disease were studied. All were ambulant patients who had had no recent gastrointestinal bleeding. The clinical, biochemical, and haematological data at the time of the investigation are shown in Tables 1  and 2 . Similar haematological and isotopic tests were carried out on six subjects who had no hepatic or haematological disease.
Indium ("1'In-oxine) solution for platelet labelling was obtained from the Radiochemical Centre, Amersham. Platelets were labelled by the optimal method of Hawker and his colleagues using 26 ml venous blood taken by clean venepuncture with an 18 gauge needle.6 Approximately 200 ,uCi were added to the platelet suspension for labelling.
To assess the effect of the labelling procedure on the platelet aggregation studies were performed on two samples, one taken from the initial platelet rich plasma and the other from the resuspended labelled platelet pellet immediately before reinjection. Aggregation was measured in a modified Born aggregometer7 using a stimulant of 1-6 ,uM ADP.
The specimens were preincubated for 15 minutes at 37°C to remove any residual prostaglandin El activity present in the buffer used in this method of "'In labelling.
For the platelet survival studies in patients and controls 5 ml venous blood were taken one hour after the injection of the labelled platelets and at intervals over the subsequent eight days. The one 
hour sample was regarded as the 100% sample and platelet survival curves were derived from measurements of radioactivity in serial whole blood samples. The mean life span was calculated by method 1 recommended by the ICSH.l Both linear and logarithmic estimates of mean platelet survival were calculated and the weighted mean of these estimates was obtained and taken to be the mean platelet survival (days).
In health approximately 30-40% of the total platelet mass is in the spleen where it exists as a slowly exchanging pool. Thus, when labelled platelets are injected 30-40% of the injected platelet bound activity enters the splenic platelet pool leaving 60-70% recoverable in the peripheral blood. The platelet recovery, therefore, bears an inverse relationship to the splenic platelet pool. Platelet recovery was calculated according to the formula:
Platelet bound activity total blood per ml of blood x volu Xb o 100 in 1 hour sample volume
Injected platelet bound activity The total blood volume was estimated from Nadler's formula.8 Spleen volume was assessed by 99mTc scintiscanning and the spleen volume was calculated according to the formula v = 0.3N/a3 where 'v' represented the volume of the spleen (ml) and 'a' the largest spleen surface area on an isotope scan.9
Results
The haematological and isotopic data concerning the 20 patients with chronic liver disease and the results of the platelet labelling studies are shown in Table 2 .
Platelet survival was linear in the six patients without haematological or liver disease with mean life span of 9-58±0-50 days (±ISD) (range 8.58-10.08). This compared with "'In platelet survivals in normal subjects in other series of 9*0±0.71 days, 9 .21±0*42 days, and 9.00 days.1012
The platelet mean life span in the patients with chronic liver disease ranged from 5-49 to 11-98 days. Twelve of these patients had reduced platelet life spans. The survival curves were dominantly linear in type with the weighted mean values of mean life span approximating closely to the linear estimates. There was no correlation between the platelet counts and mean life span (r = 0.14).
There was no relationship between platelet counts and platelet recoveries (r = -0-25), the platelet recoveries representing an inverse relationship with the splenic platelet pool. Splenic size could only be assessed accurately in 17 patients but no relationship was established between platelet count and spleen size (r = -0.46).
Discussion
In studies of platelet dynamics using an isotopic label optimal results are achieved with techniques which confer the least damage on platelets. Although the mean life span of platelets labelled with 51Cr and "'In are similarl' the 51Cr method recommended by the International Committee for Standardization in Haematology' has several disadvantages. Firstly, it involves the harvesting of platelets from 200-500 ml whole blood. Venesection of such large volumes of blood from ill and often already anaemic patients with chronic liver disease is ethically unacceptable and also results in a reactive thrombocytosis which often invalidates any 'steady state' investigations. Secondly, sodium chromate may inhibit connective tissue induced aggregation in vitro.3 Although the amount of chromium which must be bound to platelets to inhibit aggregation is 10-100 times the amount of radioactive chromium bound to platelets for standard survival studies this does not necessarily imply that chromium labelled platelets are metabolically normal.3 Thirdly, a reproducible and linear platelet loss with time is not always found with 51Cr labelled platelets.' 'llIn labelled platelets provide an excellent tool for studies with ill and possibly thrombocytopenic patients with chronic liver disease. Only 26 ml blood is required in the method described by Hawker and his colleagues6 and the system of labelling maintains platelets in a plasma-free state for only 60 s; at all other times the platelets are suspended in at least 37.5% autologous plasma. Uptake of "'In is an active process and efficient labelling of platelets is only obtained when the patients have intact metabolic and aggregation functions. 13 This contrasts with 51Cr, which is capable of diffusing into functionally nonresponsive as well as responsive platelets. Although we did not use it in this study the high photon yield of gamma emitting "'In permits excellent gamma camera imaging.2
The results of our present studies in chronic liver disease using iiIn as a label for the platelets confirms many of the previous findings in chronic liver disease using the "Cr label."1'7 Although the platelet counts in the present group of patients ranged from normal levels to as low as 20x109/l there was no significant relationship between platelet count and mean life span. The mean life span of platelets in the present series was often normal or moderately reduced, though in two patients (cases 2 and 9) it was markedly reduced to less than six days.
As with the 51Cr label in earlier work'6 17 the platelet recoveries were low, indicating large platelet pools in spleens which were not themselves particularly enlarged. Again, no clear relationship emerged between the size of the splenic pool in liver disease and the degree of thrombocytopenia. This contrasts with the previously established direct relationship between the splenic platelet pool and the spleen size which has been apparent in the haematological 'big spleen' syndromes. '8 Although the majority of patients in this present work had alcoholic cirrhosis there are no suggestions, as yet, that thrombocytopenia is more common in any particular diagnostic group of chronic liver disease.'7 In particular, thrombocytopenia is not necessarily more frequently seen in patients with active chronic hepatitis in which increased autoantibody activity is well-recognised. Recent suggestions indicate that platelet associated immunoglobulins are common in both alcoholic and non-alcoholic liver disease and that these may be of prime importance in the pathogenesis of thrombocytopenia. '9 
